Vaccine Manufacturing Limited By Mergers, Not Government – CDC Economist
The limited number of vaccine manufacturers is a result of industry consolidation rather than monopsony government buying power, National Immunization Program Economist Margaret Coleman said
You may also be interested in...
Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials